Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 9/20 | 0.42 |
| ▸ | FPR1 | P21462 | 4/20 | 0.40 |
| ▸ | FPR2 | P25090 | 4/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 3/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19521201 | 1.00 | CTSC (0.42) | CTSCFPR1FPR2TACR1CHRM3 | |
| SCHEMBL19544843 | 0.89 | CTSC (0.40) | CTSCFPR1FPR2TACR1CHRM3 | |
| SCHEMBL19544579 | 0.89 | CTSC (0.40) | CTSCFPR1FPR2TACR1CHRM3 | |
| SCHEMBL22582613 | 0.89 | CTSC (0.40) | CTSCFPR1FPR2TACR1CHRM3 | |
| SCHEMBL19544840 | 0.88 | YAP1 (0.39) | CTSCFPR1FPR2CTSK | |
| SCHEMBL19544844 | 0.88 | YAP1 (0.39) | CTSCFPR1FPR2CTSK | |
| SCHEMBL19521180 | 0.81 | PTGER4 (0.39) | CTSCCTSKF2 | |
| SCHEMBL19544841 | 0.77 | CTSC (0.69) | CTSCFPR1FPR2KCNH2CTSK | |
| SCHEMBL19521215 | 0.74 | MMP9 (0.47) | FPR1FPR2CTSKPIN1 | |
| SCHEMBL19521217 | 0.74 | MMP9 (0.47) | FPR1FPR2CTSKPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339562-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2020-10-29 | — | — | US | disclosed |
| WO-2017190048-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | X-CHEM, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339562-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | CTSC 620/4885FPR1 1139/4885FPR2 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.